{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:41:47Z","timestamp":1792500107694,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104733","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:50:35Z","timestamp":1770828635000},"page":"104733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Toward genomic personalization of breast cancer radiotherapy: foundations, challenges, and a roadmap for clinical integration"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-8110","authenticated-orcid":false,"given":"Pierre","family":"Loap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Buvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Crehange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9804","key":"10.1016\/j.breast.2026.104733_bib1","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"9935","key":"10.1016\/j.breast.2026.104733_bib2","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.breast.2026.104733_bib3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N","article-title":"Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery","volume":"56","author":"Holland","year":"1985","journal-title":"Cancer"},{"issue":"9618","key":"10.1016\/j.breast.2026.104733_bib4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"371","author":"Trialists\u2019 Group","year":"2008","journal-title":"Lancet Lond Engl"},{"issue":"31","key":"10.1016\/j.breast.2026.104733_bib5","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10237","key":"10.1016\/j.breast.2026.104733_bib6","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.breast.2026.104733_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104733_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103121","article-title":"Cardiotoxicity in breast cancer patients treated with radiation therapy: from evidences to controversies","volume":"156","author":"Loap","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijrobp.2022.01.020","article-title":"Is radiation-induced cardiac toxicity reversible? Prospective evaluation of patients with breast cancer enrolled in a phase 3 randomized controlled trial","volume":"113","author":"Abraham","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2022.04.019","article-title":"Dose to the left anterior descending artery correlates with cardiac events after irradiation for breast cancer","volume":"114","author":"Zureick","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.breast.2026.104733_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00066-025-02411-1","article-title":"Proton therapy in young breast cancer patients with germline TP53 and ATM mutations: a case series","author":"Loap","year":"2025","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"10.1016\/j.breast.2026.104733_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tipsro.2021.02.006","article-title":"Dosimetric analysis of Deep Inspiratory Breath-hold technique (DIBH) in left-sided breast cancer radiotherapy and evaluation of pre-treatment predictors of cardiac doses for guiding patient selection for DIBH","volume":"17","author":"Ferdinand","year":"2021","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00373-9","article-title":"Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers","volume":"46","author":"Bj\u00f6rk-Eriksson","year":"2000","journal-title":"Int J Radiat Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104733_bib14","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bjc.1997.531","article-title":"The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix","volume":"76","author":"West","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104733_bib15","article-title":"Genomic analysis of radiosensitivity in breast cancer : identifying pathological determinants and assessing genomic-adjusted radiation dose (GARD) for personalized dose escalation","author":"Loap","year":"2025","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"issue":"9938","key":"10.1016\/j.breast.2026.104733_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.breast.2026.104733_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9255494","article-title":"Developing ZNF gene signatures predicting radiosensitivity of patients with breast cancer","volume":"2021","author":"Yan","year":"2021","journal-title":"J Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104733_bib18","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1158\/1078-0432.CCR-17-3169","article-title":"21-Gene recurrence Score assay predicts benefit of post-mastectomy radiotherapy in T1-2 N1 breast cancer","volume":"24","author":"Goodman","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2026.104733_bib19","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1245\/s10434-024-15566-5","article-title":"The clinical utility of a 7-Gene biosignature on radiation therapy decision making in patients with ductal carcinoma in situ following breast-conserving surgery: an updated analysis of the DCISionRT\u00ae PREDICT Study","volume":"31","author":"Shah","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104733_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw256","article-title":"Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ","volume":"109","author":"Rakovitch","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.breast.2026.104733_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijrobp.2009.05.056","article-title":"Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2026.104733_bib22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/1471-2164-13-348","article-title":"Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells","volume":"13","author":"Kim","year":"2012","journal-title":"BMC Genom"},{"issue":"16","key":"10.1016\/j.breast.2026.104733_bib23","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-14-2898","article-title":"Development and validation of a novel radiosensitivity signature in human breast cancer","volume":"21","author":"Speers","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib24","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1038\/s41598-021-86681-6","article-title":"TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells","volume":"11","author":"Anbalagan","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104733_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol Lond Engl"},{"issue":"2","key":"10.1016\/j.breast.2026.104733_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2011.01.010","article-title":"Is \u03b1\/\u03b2 for breast cancer really low?","volume":"100","author":"Qi","year":"2011","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104733_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2015.06.021","article-title":"Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer","volume":"93","author":"Torres-Roca","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.breast.2026.104733_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","article-title":"A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study","volume":"18","author":"Scott","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104733_bib29","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104733_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ebiom.2019.08.019","article-title":"Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management","volume":"47","author":"Ahmed","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41525-021-00200-0","article-title":"Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy","volume":"6","author":"Dai","year":"2021","journal-title":"Npj Genomic Med"},{"key":"10.1016\/j.breast.2026.104733_bib32","article-title":"Analysis of the radiosensitivity index (RSI) in paired Pre- and post-neoadjuvant therapy triple-negative breast cancer","author":"Stecklein","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2026.104733_bib33","first-page":"127","article-title":"Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model","volume":"36","author":"Nolan","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104733_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.2003.04.171","article-title":"Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review","volume":"21","author":"Huang","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2026.104733_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113955","article-title":"Young boost randomized phase III trial of high vs low boost radiation in young breast cancer patients: 10-year results","author":"Bosma","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","article-title":"Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial","volume":"16","author":"Bartelink","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104733_bib37","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ebiom.2015.10.024","article-title":"Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of breast fibrosis after radiotherapy: results of the prospective multicenter French trial","volume":"2","author":"Azria","year":"2015","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.breast.2026.104733_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100335","article-title":"Please mind the gap\u2014about equity and access to care in oncology","volume":"6","author":"Barcellini","year":"2021","journal-title":"ESMO Open"},{"issue":"10434","key":"10.1016\/j.breast.2026.104733_bib39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.breast.2026.104733_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib41","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104733_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e13177","article-title":"Tumor heterogeneity between primary and paired recurrent breast cancer and its potential molecular mechanism","volume":"43","author":"Tan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104733_bib43","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1245\/s10434-019-07567-6","article-title":"Clinical implications of transcriptomic changes after neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"26","author":"Orozco","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13073-024-01286-8","article-title":"Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy","volume":"16","author":"Yin","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.breast.2026.104733_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2017.06.014","article-title":"Preoperative breast radiation therapy: indications and perspectives","volume":"82","author":"Lightowlers","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104733_bib46","article-title":"A therapeutic challenge: Chemo-refractory non-metastatic inflammatory breast cancers","volume":"34","author":"Loap","year":"2022","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"10.1016\/j.breast.2026.104733_bib47","article-title":"Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer","author":"Loap","year":"2022","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"issue":"5","key":"10.1016\/j.breast.2026.104733_bib48","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/tbj.13764","article-title":"Outcomes of exclusive radiation therapy for older women with breast cancer according to age and comorbidity status: an observational retrospective study","volume":"26","author":"Cao","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2026.104733_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ebiom.2018.07.036","article-title":"Circular RNAs: promising biomarkers for human diseases","volume":"34","author":"Zhang","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib50","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12880-025-01968-8","article-title":"The feasibility of the radiomics models for tumor-infiltrating lymphocytes level prediction in breast cancer based on dynamic contrast-enhanced MRI","volume":"25","author":"Peng","year":"2025","journal-title":"BMC Med Imag"},{"issue":"4","key":"10.1016\/j.breast.2026.104733_bib51","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2967\/jnumed.123.266749","article-title":"PET\/CT-Based radiogenomics supports KEAP1\/NFE2L2 Pathway targeting for non\u2013small cell lung cancer treated with curative radiotherapy","volume":"65","author":"Bourbonne","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104733_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102963","article-title":"Optimal co-clinical radiomics: sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging","volume":"59","author":"Roy","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.breast.2026.104733_bib53","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2011.11.035","article-title":"[18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment","volume":"48","author":"Soloviev","year":"2012","journal-title":"Eur J Cancer"},{"issue":"55","key":"10.1016\/j.breast.2026.104733_bib54","doi-asserted-by":"crossref","first-page":"94969","DOI":"10.18632\/oncotarget.21662","article-title":"18F-Fluoromisonidazole in tumor hypoxia imaging","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2026.104733_bib55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2022.03.021","article-title":"Dose escalation to hypoxic subvolumes in head and neck cancer: a randomized phase II study using dynamic [18F]FMISO PET\/CT","volume":"171","author":"Welz","year":"2022","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13058-018-0970-6","article-title":"Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer","volume":"20","author":"Asano","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104733_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e14371","article-title":"A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images","volume":"9","author":"Verdicchio","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41698-025-00866-0","article-title":"Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning","volume":"9","author":"Zhang","year":"2025","journal-title":"npj Precis Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104733_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-024-07350-6","article-title":"Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis","volume":"207","author":"Zhuo","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.breast.2026.104733_bib60","article-title":"A pathomics-integrated multimodal model to evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinoma","volume":"7","author":"Cao","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.breast.2026.104733_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.radphyschem.2024.111649","article-title":"Digital twins in dosimetry and radiotherapy, a survey and some applications","volume":"218","author":"Sumini","year":"2024","journal-title":"Radiat Phys Chem"},{"key":"10.1016\/j.breast.2026.104733_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2023.1222612","article-title":"Predictive digital twin for optimizing patient-specific radiotherapy regimens under uncertainty in high-grade gliomas","author":"Chaudhuri","year":"2023","journal-title":"Front Artif Intell"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:30:52Z","timestamp":1775683852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":62,"alternative-id":["S0960977626000433"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104733","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward genomic personalization of breast cancer radiotherapy: foundations, challenges, and a roadmap for clinical integration","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104733"}}